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Results: Negative results were approximately four times higher
than positive results (334: 76) through virus isolation. The ratio
of males to females in the positive group was 1.2: 1. The highest
positive age groups were 10-19 years (30.8%), followed by 20-
29 years (23.2%), and 30-39 years (22.4%) respectively. Signs and
symptoms most frequently found were sneezing (46.2%) and sore
throats (24.1%).
When comparing both methods, quantitative real time RT-PCR
indicated 85 positive and 325 negative specimens. On the other
hand, using virus isolation, 76 TS specimens were positive and
334were negative. Sensitivity, speciﬁcity, positive predictive value
(PPV), negative predictive vakue (NPV), and accuracy of quantita-
tive real time RT-PCR assay were 100%, 97.3%, 89.4%, 100%, and
97.8% respectively.
Conclusion: In conclusion, quantitative real time RT-PCR can
be used for routine diagnosis as part of inﬂuenza surveillance and
support in future inﬂuenza outbreaks with the advantages of high
sensitivity, high speciﬁcity, safety from the carcinogen reagents,
and less time consuming when compared with the virus isolation
assay
http://dx.doi.org/10.1016/j.ijid.2014.03.1333
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Background: Recommendations on the treatment of chronic
hepatitis B (CHB) are evolving and are constantly renewed in accor-
dance with the new literature. Guidelines play a major role in
these recommendations. In this study, we aimed to take care of
the dilemma between real-life and guideline recommendations.
Methods & Materials: Primary non-response (PNR) is deﬁned
as less than 1 log10 IU/ml decrease in HBV DNA level from baseline
at 3 months of therapy. Early switch to a more potent drug in PNR
cases is recommended after conﬁrming the patient’s compliance.
Results: A total of 127 patients’ records were reviewed. Five
of them were HBeAg pozitif and 122 of them were HBeAg nega-
tive CHB. PNR was observed in six patients among HBeAg negative
group. In contrast to guideline recommendations, we detected that
lamivudine treatmentwas continued in these patients. Lamivudine
therapy was stopped in the sixth month of therapy in two of them
due to detectable HBVDNA. However, undetectable HBVDNA level
was observed in four of them and lamivudine therapy was contin-
ued again. Lamivudine therapy in these patients is still continued
with the mean duration of 27 months. Baseline characteristics of
PNR patients with and without undetectable HBV DNA at the sixth
month of lamivudine treatment were presented in Table 1.
Conclusion: Although guidelines deﬁned the primary non-
response asless than 1 log10 IU/mldecrease in HBV DNA level from
baseline at 3 months of therapy, this deﬁnition does not work in
Table 1
Baseline characteristics of primary non-responsers with and without undetectable HBV DNA at the sixth month of treatment
Characteristics Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Gender Female Female Male Male Male Male
Age (years) 31 28 48 39 38 47
Histological activity index 4 4 5 15 7 7
Fibrosis 2 2 2 4 4 2
Baseline HBV DNA (IU/mL) 4944 1.940.000 7.790 40.700 1.960.000 702.000
ALT (U/L) 62 66 60 25 169 58
AST (U/L) 34 33 47 21 64 31
HBV DNA (IU/mL)
At 3rd month
At 6th month 3538 508.000 4760 13300 956.000 523.000
At 12th month 0 0 0 0 19 49.100
At 20th month 0 0 0 0 switched switched
At 30th month (Continues) (continues) 0(continues) 0(continues) - -
At 40th month
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four of 6 PNR cases. We think that, the deﬁnitions in the guidelines
should be revised with real- life experiences. In our opinion, PNR
shouldbe evaluated in the sixthmonthof treatment insteadof third
month.
http://dx.doi.org/10.1016/j.ijid.2014.03.1334
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Background: Lamivudine therapy in chronic hepatitis B (CHB)
treatment is not encouraged because of its lower resistance bar-
rier. In this study, we aimed to investigate the long-term efﬁcacy
of lamivudine treatment in HBeAg negative CHB patients.
Methods & Materials: This retrospective study is conducted in
three different tertiary care hospitals. Virological response (VR) is
deﬁned as undetectable HBV DNA by a sensitive PCR assay during
therapy. Partial virological response (PVR) is deﬁned as a decrease
in HBV DNA of more than 1 log10 IU/ml but detectable HBV DNA
after at least 6 months of therapy in compliant patients. Virologi-
cal breakthrough also called as relapse is deﬁned as a conﬁrmed
increase in HBV DNA level of more than 1 log10 IU/ml compared to
the lowest value of HBV DNA level on therapy.
Results: A total of 145 patients (57,9% male) were evaluated.
Theirmean agewas 44,6 years and 23 (15,9%) of themwere treated
with interferons previously. The median value of the ISHAK histo-
logical activity index (HAI) and ﬁbrosis were 6 (range: 2-16) and 1
(range: 1-5). Themeanvalue of ALT, AST, andHBVDNAwere57U/L,
42 U/L and 1.189.806 IU/mL, respectively. Treatment of ﬁfty-three
(36,6%) patientswas switched tomore potent drugs due to PVR (29;
20%) or relapse (24; 16,6%). Relapse was observed between 13 and
36 months in majority of relapsers (12 cases in 13 to 24 months
and 8 cases in 25 to 36 months). VR was observed in 92 (63,4%) and
their median time on lamivudine therapy was 34,5 months (range:
6-78 months). Baseline characteristics of virologic responders and
switched group were shown in Table 1.
Conclusion: Our results showed that more than 60% patients
maintain viral suppression more than thirty months. Lamivudine
can still be a reliable drug especially in low-income countries
because of its low cost. However, lamivudine should be used with
more caution in patients who have low thrombocyte and high HAI,
ﬁbrosis, ALT, and AST levels.
http://dx.doi.org/10.1016/j.ijid.2014.03.1335
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Background: Acute respiratory tract infections (ARTIs) are a
signiﬁcant cause of morbidity and account for a major percent-
age of mortality in early childhood worldwide. Viral infections are
responsible for most respiratory infections.
Methods & Materials: Nasopharyngeal aspirates (NPA) speci-
mens were collected from 1800 pediatric patients who suspected
acute respiratory infection in Southern China Samples were
screened for 21 kinds of respiratory viruses by multiplex reverse
transcription-PCR(RT-PCR) with a GenomeLab Gene Expression
Proﬁler (GeXP) analyzer.
Results: A total of 67.33%(1212/1800) of samples were
positive for at least one virus. The 1212 positive specimens
included 475 human rhinovirus(HRV),356 respiratory syncytial
virus (RSV),160 human adenovirus(HADV),117 human parain-
ﬂuenza 3(HPIV-3),96 human bocavirus (HBoV), 96 Inﬂuenza A
(including 39 swine H1N1,21 inﬂuenza virus H3N2,9 seasonal
H1N1,6 inﬂuenza virus H2N2 and 21 etc inﬂuenza A virus),60
human parainﬂuenza 4(HPIV-4), 33 human coronaviruses NL63
and 229E(HCoV-NL63/229E), 27 Inﬂuenza C(Inf C), 20 human
metapneumovirus (hMPV), 15 HCoV-HKU1/OC43, 12 Inf B, 9 HPIV-
1, 9 WU polyomaviruses(WUPyV) and 3 HPIV-2. Co-infection by at
least 2 of the viral pathogens under study was observed in 13.5%
cases (243/1800).
Conclusion: This is a rapid and simple assay that could be used
in clinical diagnosis as well as for the surveillance for the spread of
antibiotic resistance determinants in epidemiological studies.
http://dx.doi.org/10.1016/j.ijid.2014.03.1336
Table 1
Baseline Characteristics Virologic responders n=92 (mean) Switched Group n=53 (mean) P value
Gender (M/F) (n) 48/44 36/17 0.06
HAI 5,9 6,9 0.01
Fibrozis 2,2 2,6 0.01
ALT (U/L) 52,4 63,8 0.009
AST (U/L) 39,2 46,9 0.008
HBV DNA (IU/mL) 1.262.186 1.063.139 0.03
